Abstract

BackgroundGenetic variations in the IL-27 gene have been proven to be associated with various types of human cancers and diseases. The purpose of the current study was to clarify the associations of the IL-27 rs153109 A>G and rs181206 T>C variants with human diseases using a meta-analysis study.Material/MethodsA comprehensive electronic and manual search was carried out to find potential eligible studies. The effect size was represented by the unadjusted odds ratios (ORs). A 95% confidence interval (95%CI) was tested for the pooled OR using the Z test.ResultsA total of 17 case-control studies (cases=4185, healthy controls=4077) were included in our study. Our study showed that the carriers of the rs181206 T>C and rs153109 A>G polymorphism in the IL-27 gene have elevated risks of diseases in the allele model (rs181206 T>C: OR=0.76, 95%CI=0.69~0.84, P<0.001; rs153109 A>G: OR=0.85, 95%CI=0.76~0.94, P=0.002) and dominant model (rs181206 T>C: OR=0.77, 95%CI=0.69~0.87, P<0.001; rs153109 A>G: OR=0.84, 95%CI=0.71~0.99, P=0.033). Disease type-stratified subgroup analysis yielded increased risk of related diseases in IL-27 rs181206 T>C carriers in the allele model in immune thrombocytopenia (ITP), asthma, and esophageal cancer (EC) subgroups (ITP: OR=0.69, 95%CI=0.53~0.88, P=0.004; asthma: OR=0.60, 95%CI=0.41~0.89, P=0.010; EC: OR=0.79, 95%CI=0.64~0.97, P=0.026); and IL-27 rs153109 A>G polymorphism was remarkably associated with the increased risk of related diseases in the allele model in ovarian cancer (OC), systemic lupus erythematosus (SLE), tuberculosis (TB), ulcerative colitis (UC), and chronic obstructive pulmonary disease (COPD) subgroups (all P<0.05).ConclusionsOur results indicate that the genetic polymorphisms of IL-27 rs153109 and rs181206 may be involved in the progression of human cancers and diseases, especially of TB, UC, COPD, OC, and ITP.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.